An observational study in Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy and HCM - Hypertrophic Cardiomyopathy, sponsored by University Hospital Heidelberg. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-30.
Sponsored by University Hospital Heidelberg · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Cardiomyopathy, Dilated with a site in Germany — 4 open to participants now, 5 under way, none of them phase 3. Cardiomyopathy, Dilated · Germany.
Among the 23 studies in Cardiomyopathy, Dilated with a site in Germany, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2020, is one of 11 observational ones, and was the 16th registered.
256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.
Browse Cardiomyopathy, Dilated studies →4 of the 23 studies in Cardiomyopathy, Dilated with a site in Germany are open now. Recruiting first, the newest first:
University Hospital, Essen · Sites in Germany
Ages 18+
Prof. Dr. med. Ingo Eitel · Sites in Germany
Ages 18+
Sana Hanse Hospital Wismar · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 2
First in 2001; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,040 is above the median of 250 across 97 observational studies indexed under Cardiomyopathy, Dilated.
Median enrollment 72 across the 12 interventional studies, 750 across the 11 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 23 have an industry lead sponsor. The 10 most frequent:
University Hospital Heidelberg is the lead sponsor of 177 studies on the registry; 48 are open to participants now.
University Hospital Heidelberg has 3 studies filed under Cardiomyopathy, Dilated — fewer than ten, so there is no comparison to draw.
1 of the studies in Cardiomyopathy, Dilated with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04558723Prof. Dr. med. Ingo EitelCardiac Magnetic Resonance Guidance of Implantable Cardioverter Defibrillator Implantation in Non-ischemic Dilated Cardiomyopathy | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Cardiomyopathy, Dilated with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients were recruited as planned. Taken together, patient data showed that the prevalence of these diseases is much higher in men than in women, atrial fibrillation is common in all forms of CMPs as well as rare forms of disease indicate a higher risk and higher morbidity.
This DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The second phase DZHK TORCH-Plus consists of 4 main modules: 1. "Clinical phenotyping, follow-up \& biosampling" 2. "Genomics", 3. "Inflammation" and 4. "Biomarker". The central aims are 1) to significantly increase the number of probands (n = 4340) in order to better address the different types of CMPs, especially patients with rare CMP forms such as LVNC and ARVC or with probably molecularly explainable cardiomyopathies (familial DCM), 2) to prolong the longitudinal with a further follow-up to achieve sufficient events and thereby derive clinical recommendations for risk assessment, 3) to increase the number of probands with state-of-the-art phenotyping, 4) to pinpoint the effect of myocardial inflammation, fibrosis, gender and to determine or predict genotypes based for outcome, 5) to validate novel biomarkers developed in other DZHK studies, and 6) to foster active cooperation with international CMP registries and partners from industry.
Primary care clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Plus inclusion / exclusion - SOP:
Dilated Cardiomyopathy (DCM)
Left ventricular hypertrophy
Left ventricular non-compaction cardiomyopathy (LVNC)
Arrhythmogenic right ventricular cardiomyopathy (ARVC / D)
Exclusion Criteria:
The following exclusion criteria have been defined and must be taken from the TORCH-Plus specific inclusion / exclusion - SOP in detail:
Patient has other (cardiac) previous illnesses:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all-cause mortality
Time frame: 4 years
Started Aug 2020 (actual). Primary completion is estimated for Dec 2027, 88 months after the start.
Of 51 observational studies under Cardiomyopathy, Dilated, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 101. This study's planned 88 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Heidelberg →